Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Immunotherapy has recently become a main-stream treatment option in cancer care, with improved clinical outcomes in many malignancies, especially that of lung cancer. The long-term benefits of this treatment however are limited. There is therefore a critical need to distinguish predictive biomarkers of response from those of resistance, and to develop synergistic strategies for improved therapeutic response. Strong emerging evidence indicates that the gut microbiome has the ability to influence response to immunotherapy. Unlike tumor genomics, the gut microbiome is modifiable, and thus its mod

Trial Details

NCT ID
NCT05502913
Phase
PHASE2
Sponsor
Soroka University Medical Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Antibiotics
  • FMT (Fecal Microbiota Transplantation)
Locations (sample)
  • Beersheba, Israel|31.25181,34.7913
  • Petah Tikva, Israel|32.0888,34.88666

Key Eligibility Criteria

  • A histologically confirmed diagnosis of malignancy.
  • Patients over the age of 18.
  • Patients planning to be treated with chemotherapy, immune checkpoint inhibitors and/or targeted therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →